TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
Authors:
- 14 April 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (8) , 1345-1360
Abstract
Study of genomic aberrations leading to immortalization of epithelial cells has been technically challenging due to the lack of isogenic models. To address this, we used healthy primary breast luminal epithelial cells of different genetic ancestry and their hTERT-immortalized counterparts to identify transcriptomic changes associated with immortalization. Elevated expression of TONSL (Tonsoku-like, DNA repair protein) was identified as one of the earliest events during immortalization. TONSL, which is located on chromosome 8q24.3, was found to be amplified in approximately 20% of breast cancers. TONSL alone immortalized primary breast epithelial cells and increased telomerase activity, but overexpression was insufficient for neoplastic transformation. However, TONSL-immortalized primary cells overexpressing defined oncogenes generated estrogen receptor–positive adenocarcinomas in mice. Analysis of a breast tumor microarray with approximately 600 tumors revealed poor overall and progression-free survival of patients with TONSL-overexpressing tumors. TONSL increased chromatin accessibility to pro-oncogenic transcription factors, including NF-κB and limited access to the tumor-suppressor p53. TONSL overexpression resulted in significant changes in the expression of genes associated with DNA repair hubs, including upregulation of several genes in the homologous recombination (HR) and Fanconi anemia pathways. Consistent with these results, TONSL-overexpressing primary cells exhibited upregulated DNA repair via HR. Moreover, TONSL was essential for growth of TONSL-amplified breast cancer cell lines in vivo, and these cells were sensitive to TONSL–FACT complex inhibitor CBL0137. Together, these findings identify TONSL as a regulator of epithelial cell immortalization to facilitate cancer initiation and as a target for breast cancer therapy. Significance: The chr.8q24.3 amplicon-resident gene TONSL is upregulated during the initial steps of tumorigenesis to support neoplastic transformation by increasing DNA repair and represents a potential therapeutic target for treating breast cancer.Keywords
All Related Versions
Funding Information
- Susan G. Komen (SAC110025)
- Office of Extramural Research (P30CA082709-22)
- Breast Cancer Research Foundation
This publication has 57 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Suppression of heat shock protein 27 induces long-term dormancy in human breast cancerProceedings of the National Academy of Sciences, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- RNAi‐based screening identifies the Mms22L–Nfkbil2 complex as a novel regulator of DNA replication in human cellsThe EMBO Journal, 2010
- The MMS22L-TONSL Complex Mediates Recovery from Replication Stress and Homologous RecombinationMolecular Cell, 2010
- A Genome-wide Camptothecin Sensitivity Screen Identifies a Mammalian MMS22L-NFKBIL2 Complex Required for Genomic StabilityMolecular Cell, 2010
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006